Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
Treatment and cost relationship on visual acuity improvement in age-associated macular degeneration
CONCLUSION: AntiVEGF treatments (ranibizumab, aflibercept and both) maintained VA in patients with exudative AMD. In general, care and treatment costs were lower in the group that received both drugs.PMID:38009288 | DOI:10.23938/ASSN.1052 (Source: Anales del Sistema Sanitario de Navarra)
Source: Anales del Sistema Sanitario de Navarra - November 27, 2023 Category: General Medicine Authors: Josep-Oriol Casanovas-Marsal Elisa Vilad és Palomar Francisco de As ís Bartol-Puyal Rub én Hernández Vian Luis E Pablo J úlvez Source Type: research
